Biotech Startups

1 investor

Allyx Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve and protect synapses in people with neurodegenerative diseases. Its lead compound, ALX-001, is a first-in-class oral therapy acting at mGluR5, currently in Phase 1b clinical development for Alzheimer's disease.

1 investor

Aloe Therapeutics develops AIM-001, a localized cell-based immunotherapy implanted at a tumor site during biopsy or resection surgery to activate the immune system and make patients more responsive to checkpoint immunotherapy. It targets advanced solid tumors across multiple tumor types and disease stages.

1 investor

Alp Bio operates a platform that combines human tonsil organoid technology with protein AI models to assess and reduce immunogenicity (anti-drug antibody) risk in therapeutic antibodies before clinical development. It serves biologics developers with in-silico ADA screening, ex vivo tonsil organoid assays, and generative redesign of antibody sequences.

1 investor

Alpenglow Biosciences develops AI-enabled 3D tissue imaging and spatial profiling platforms for researchers and clinical teams in pathology and diagnostics. The company's patented light-sheet microscopy technology provides volumetric tissue data for analysis and clinical discovery applications.

1 investor

A biopharmaceutical company developing oncology treatments including EGFR-targeting small molecule drugs for lung cancer with CNS penetration, and expanding into cell immunotherapy through licensed partnerships for NK cell and CAR-T therapies targeting solid tumors and hematologic malignancies.

1 investor

Alphyn Biologics develops Multi-Target Therapeutics based on its Zabalafin (AB-101) platform to treat skin diseases, with a lead candidate, zabalafin hydrogel, a non-steroidal topical treatment for atopic dermatitis in children and adults that targets itch, inflammation, and Staph bacteria. The company operates in the biotech/dermatology drug development sector and has completed a Phase 2a clinical trial.

1 investor

Alsteni Medical develops an intraoral gastrointestinal access device designed to deliver nutrient therapy for metabolic management. The company is advancing the device through FDA 510(k) clearance with clinical evidence and manufacturing partnerships in place.

1 investor

Atlas AI provides wet-lab, bioinformatics, and AI services on a modular, expert-led basis, helping clients with experimental execution, data generation, analytical pipelines, and deployed software systems. It serves partners across biotech, healthtech, and industrial domains, from early-stage research through applied R&D and pre-industrial development.

1 investor

Altach Biomedical develops cartilage repair solutions for the orthopedic medical device industry. The company showcases its innovative technologies at major MedTech conferences to engage with investors and strategic partners.

1 investor

Alta Partners is a venture capital firm focused on life sciences and healthcare investments, with a portfolio that has generated over 90 FDA-approved products and includes both therapeutic companies and tech-enabled patient care services.

1 investor

ALTDATA builds physics-anchored digital twins and privacy-safe synthetic data to address data scarcity for research-intensive teams in biotech, healthcare, and space. The Adelaide-based company serves biomedical researchers and space agencies who face barriers to accessing or generating experimental data.

1 investor

AlterDiag is a diagnostics company founded by executives with backgrounds in immunology R&D and business strategy. The page focuses on the founding team and does not detail the specific product beyond its work in the diagnostics market.

1 investor

Alter Echo develops technology that keeps personnel outside cleanrooms while reducing disposable gown waste in pharmaceutical manufacturing. The company targets pharmaceutical facilities seeking to improve workplace safety, environmental sustainability, and operational efficiency.

1 investor

ABio-X is a life sciences incubation platform that creates and invests in biotech and pharmaceutical companies developing innovative medicines and technologies. The platform provides capital, operational support, and access to experienced entrepreneurs and industry networks to accelerate drug development pipelines.

1 investor

Alteron Therapeutics is a pharmaceutical company focused on drug innovation. The available page does not detail its specific therapeutic areas or products.

1 investor

1 investor

1 investor

Altratech develops point-of-care diagnostic technology for quantitative HIV viral load testing in low- and middle-income countries. The company creates affordable and accessible medical devices for resource-limited healthcare settings.

1 investor

AltrixBio develops AJN003, a non-systemic, once-daily oral therapy for type 2 diabetes and related metabolic conditions that transiently coats the stomach and upper intestine to shift nutrient sensing and trigger a metabolic reset similar to bariatric surgery. The drug targets glycemic control and weight loss and is positioned as a complement or alternative to incretin-based (GLP-1) treatments, with potential applications in broader cardiometabolic diseases.

1 investor

Altum Sequencing develops molecular sequencing assays for oncology programs, supporting pharmaceutical companies and healthcare providers in biomarker strategy, companion diagnostic development, and post-approval patient monitoring in cancer treatment.

1 investor

1 investor

Aluna Data provides a benchmarking suite for oncology AI models, offering standardized datasets including over 2 million whole slide images across 25+ tumor types with pathologist annotations, whole genome sequencing data, and clinical information for cancer research and AI development.

1 investor

AlveoGene develops respiratory gene therapies, led by executives and academic researchers from the UK Respiratory Gene Therapy Consortium.

1 investor